The Center for Drug Evaluation and Research (CDER) has announced that it plans to continue a program which allows pharmaceutical companies to invite regulators to visit their manufacturing sites to ...

This piece is the first in a series exploring the foundational players in the U.S. healthcare system: payers, providers, policymakers, and the pharmaceutical industry. Ever since Bill and Hillary ...

When patients are prescribed complex therapies — like specialty drugs, cell and gene treatments, or high-cost biologics — the path to treatment is rarely straightforward. Filling a prescription can ...

Define Ventures’ new report provides a clear framework for how enterprise healthcare, particularly Big Pharma, is transitioning from AI exploration to execution. It focuses on core categories, ...

As pharmaceutical companies face increasing pressure to produce more content across more channels, the Medical, Legal, and Regulatory (MLR) review process is under strain. What was once a structured, ...